{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:17:36Z","timestamp":1794579456675,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["104169\/Z\/14\/A"],"award-info":[{"award-number":["104169\/Z\/14\/A"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    is a significant cause of otitis media, pneumonia, and meningitis. Only seven of the approximately 100 serotypes were initially included in the pneumococcal\u00a0polysaccharide conjugate vaccine (PCV) in 2000 before it was expanded in subsequent years. Although the invasive pneumococcal disease (IPD) incidence due to vaccine serotypes (VT) has declined, partial replacement by non-vaccine serotypes (NVT) was observed following widespread vaccine uptake. We conducted a trend analysis assembling the available evidence for PCV impact on European, North American and Australian national IPD. Significant effectiveness against VT IPD in infants was observed, although the impact on national IPD incidence varied internationally due to serotype replacement. Currently, NVT serotypes 8, 9N, 15A and 23B are increasing in the countries assessed, although a variety of other NVTs are affecting each country and age group. Despite these common emerging serotypes, there has not been a dominant IPD serotype post-vaccination as there was pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), suggesting that future vaccines with additional serotypes will be less effective at targeting and reducing IPD in global populations than previous PCVs. The rise of diverse NVTs in all settings\u2019 top-ranked IPD-causing serotypes emphasizes the urgent need for surveillance data on serotype distribution and serotype-specific invasiveness post-vaccination to facilitate decision making concerning both expanding current vaccination programmes and increasing vaccine valency.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-75691-5","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T06:03:36Z","timestamp":1604469816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency"],"prefix":"10.1038","volume":"10","author":[{"given":"Alessandra","family":"L\u00f8chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"issue":"9693","key":"75691_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O'Brien","year":"2009","unstructured":"O\u2019Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 374(9693), 893\u2013902 (2009).","journal-title":"Lancet"},{"key":"75691_CR2","unstructured":"European Centre for Disease Prevention and Control, Disease factsheet about pneumococcal disease (2020)."},{"key":"75691_CR3","unstructured":"WHO. Pneumococcal disease. 2017. Accessed on June 22, 2017. https:\/\/www.who.int\/immunization\/diseases\/pneumococcal\/en\/."},{"key":"75691_CR4","unstructured":"CDC. Active Bacterial Core Surveillance (ABCs) report emerging infections program network: Streptococcus pneumoniae, provisional-2014. 2014 September 28, 2015. Accessed on June 22, 2017. https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu14.pdf."},{"issue":"1","key":"75691_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1473-3099(07)70242-6","volume":"8","author":"SJ Bliss","year":"2008","unstructured":"Bliss, S. J. et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect. Dis. 8(1), 67\u201380 (2008).","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"75691_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/civ059","volume":"60","author":"C von Mollendorf","year":"2015","unstructured":"von Mollendorf, C. et al. Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed but uninfected infants aged < 1 year in South Africa, 2009\u20132013. Clin. Infect. Dis. 60(9), 1346\u20131356 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"75691_CR7","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1097\/INF.0000000000000078","volume":"33","author":"L Conklin","year":"2014","unstructured":"Conklin, L. et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr. Infect. Dis. J. 33(Suppl 2), S109\u2013S118 (2014).","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"2","key":"75691_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1056\/NEJMoa1209165","volume":"369","author":"MR Griffin","year":"2013","unstructured":"Griffin, M. R. et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 369(2), 155\u2013163 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"75691_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/INF.0000000000000451","volume":"33","author":"C Levy","year":"2014","unstructured":"Levy, C. et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr. Infect. Dis. J. 33(12), 1216\u20131221 (2014).","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"27","key":"75691_CR10","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","volume":"32","author":"S Ben-Shimol","year":"2014","unstructured":"Ben-Shimol, S. et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: An active prospective nationwide surveillance. Vaccine 32(27), 3452\u20133459 (2014).","journal-title":"Vaccine"},{"issue":"8","key":"75691_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/ciu524","volume":"59","author":"ZB Harboe","year":"2014","unstructured":"Harboe, Z. B. et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin. Infect. Dis. 59(8), 1066\u20131073 (2014).","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"75691_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","volume":"14","author":"NJ Andrews","year":"2014","unstructured":"Andrews, N. J. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A postlicensure indirect cohort study. Lancet Infect. Dis. 14(9), 839\u2013846 (2014).","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"75691_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","volume":"11","author":"E Miller","year":"2011","unstructured":"Miller, E. et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet. Infect. Dis 11(10), 760\u2013768 (2011).","journal-title":"Lancet. Infect. Dis"},{"issue":"10","key":"75691_CR14","doi-asserted-by":"publisher","first-page":"e1000348","DOI":"10.1371\/journal.pmed.1000348","volume":"7","author":"HL Johnson","year":"2010","unstructured":"Johnson, H. L. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project. PLoS Med. 7(10), e1000348 (2010).","journal-title":"PLoS Med."},{"issue":"1","key":"75691_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1086\/313608","volume":"30","author":"WP Hausdorff","year":"2000","unstructured":"Hausdorff, W. P. et al. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30(1), 100\u2013121 (2000).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"75691_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","volume":"32","author":"SM Davis","year":"2013","unstructured":"Davis, S. M. et al. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects. Vaccine 32(1), 133\u2013145 (2013).","journal-title":"Vaccine"},{"issue":"10","key":"75691_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","volume":"11","author":"E Miller","year":"2011","unstructured":"Miller, E. et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: An observational cohort study. Lancet Infect. Dis. 11(10), 760\u2013768 (2011).","journal-title":"Lancet Infect. Dis."},{"issue":"43","key":"75691_CR18","first-page":"434","volume":"85","author":"WHO","year":"2010","unstructured":"WHO. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly. Epidemiol. Rec. 85(43), 434\u2013436 (2010).","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"9807","key":"75691_CR19","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","volume":"378","author":"DM Weinberger","year":"2011","unstructured":"Weinberger, D. M., Malley, R. & Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 378(9807), 1962\u20131973 (2011).","journal-title":"Lancet"},{"issue":"1","key":"75691_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-micro-090817-062338","volume":"72","author":"NJ Croucher","year":"2018","unstructured":"Croucher, N. J., L\u00f8chen, A. & Bentley, S. D. Pneumococcal vaccines: Host interactions, population dynamics, and design principles. Annu. Rev. Microbiol. 72(1), 521\u2013549 (2018).","journal-title":"Annu. Rev. Microbiol."},{"issue":"3","key":"75691_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","volume":"15","author":"MR Moore","year":"2015","unstructured":"Moore, M. R. et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance. Lancet. Infect. Dis 15(3), 301\u2013309 (2015).","journal-title":"Lancet. Infect. Dis"},{"key":"75691_CR22","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","volume":"19","author":"JA Lewnard","year":"2019","unstructured":"Lewnard, J. A. & Hanage, W. P. Making sense of differences in pneumococcal serotype replacement. Lancet Infect. Dis. 19, e213\u2013e220 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"75691_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12879-015-1147-x","volume":"15","author":"M Tin Tin Htar","year":"2015","unstructured":"Tin Tin Htar, M., Christopoulou, D. & Schmitt, H.-J. Pneumococcal serotype evolution in Western Europe. BMC Infect. Dis. 15, 419 (2015).","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"75691_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/aje\/154.1.85","volume":"154","author":"M Lipsitch","year":"2001","unstructured":"Lipsitch, M. Interpreting results from trials of pneumococcal conjugate vaccines: A statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. Am. J. Epidemiol. 154(1), 85\u201392 (2001).","journal-title":"Am. J. Epidemiol."},{"issue":"11","key":"75691_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/j.1469-0691.2009.02775.x","volume":"15","author":"R Sa-Leao","year":"2009","unstructured":"Sa-Leao, R. et al. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 15(11), 1002\u20131007 (2009).","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"75691_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1086\/648593","volume":"201","author":"T Pilishvili","year":"2010","unstructured":"Pilishvili, T. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32\u201341 (2010).","journal-title":"J. Infect. Dis."},{"issue":"8","key":"75691_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/521833","volume":"196","author":"KL O'Brien","year":"2007","unstructured":"O\u2019Brien, K. L. et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211\u20131220 (2007).","journal-title":"J. Infect. Dis."},{"issue":"9824","key":"75691_CR28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)60589-3","volume":"379","author":"WP Hausdorff","year":"2011","unstructured":"Hausdorff, W. P., Van Dyke, M. K. & Van Effelterre, T. Serotype replacement after pneumococcal vaccination. Lancet 379(9824), 1387\u20131388 (2011).","journal-title":"Lancet"},{"issue":"8","key":"75691_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S2213-2600(17)30110-8","volume":"5","author":"C Savulescu","year":"2017","unstructured":"Savulescu, C. et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: An observational multicentre study. Lancet Respir. Med. 5(8), 648\u2013656 (2017).","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"75691_CR30","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1017\/S0950268817001194","volume":"145","author":"M Corcoran","year":"2017","unstructured":"Corcoran, M. et al. The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?. Epidemiol. Infect. 145(11), 2390\u20132399 (2017).","journal-title":"Epidemiol. Infect."},{"issue":"5","key":"75691_CR31","first-page":"396","volume":"9","author":"R Lapidot","year":"2020","unstructured":"Lapidot, R. et al. Characteristics of serotype 3 invasive pneumococcal disease before and after universal childhood immunization with PCV13 in Massachusetts. Pathogens (Basel, Switzerland) 9(5), 396 (2020).","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"75691_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/INF.0000000000002549","volume":"39","author":"M Corcoran","year":"2019","unstructured":"Corcoran, M. et al. Invasive Streptococcus pneumoniae infections and vaccine failures in children in ireland from the postvaccine Era From 2007 to 2018. Pediatr. Infect. Dis. J. 39, 339\u2013344 (2019) (Online First).","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"5","key":"75691_CR33","doi-asserted-by":"publisher","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","volume":"12","author":"E Balsells","year":"2017","unstructured":"Balsells, E. et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS ONE 12(5), e0177113 (2017).","journal-title":"PLoS ONE"},{"issue":"3","key":"75691_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41564-019-0651-y","volume":"5","author":"C Colijn","year":"2020","unstructured":"Colijn, C., Corander, J. & Croucher, N. J. Designing ecologically optimized pneumococcal vaccines using population genomics. Nat. Microbiol. 5(3), 473\u2013485 (2020).","journal-title":"Nat. Microbiol."},{"key":"75691_CR35","unstructured":"The World Bank. High Income. [cited 2019 July 18]. https:\/\/data.worldbank.org\/income-level\/high-income."},{"issue":"11","key":"75691_CR36","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1128\/JCM.39.11.4190-4192.2001","volume":"39","author":"H Grundmann","year":"2001","unstructured":"Grundmann, H., Hori, S. & Tanner, G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J. Clin. Microbiol. 39(11), 4190\u20134192 (2001).","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"75691_CR37","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","volume":"9","author":"S-Y Chen","year":"2017","unstructured":"Chen, S.-Y., Feng, Z. & Yi, X. A general introduction to adjustment for multiple comparisons. J. Thorac. Dis. 9(6), 1725\u20131729 (2017).","journal-title":"J. Thorac. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75691-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:12:54Z","timestamp":1670346774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75691-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75691"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75691-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL is funded by an investigator-initiated grant from GSK to NJC. NJC has consulted for Antigen Discovery, Inc. RMA has been a non-executive director of GlaxoSmithKline for the period 2009 to 2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18977"}}